Physician profile
Robert Perello
NPI 1780672717
$1,373.61
in general payments reported to CMS, 2019-2025
13 companies · $224 in 2025
The $224 reported for 2025 was more than what 77% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $106 · 2021: $189 · 2022: $110 · 2023: $310 · 2024: $299 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $405.72 | 2019-2025 | Bexsero, Pediarix |
| Pfizer INC. | $288.94 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $186.30 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi Pasteur INC. | $124.07 | 2019-2024 | |
| Cumberland Pharmaceuticals, INC. | $109.83 | 2023-2025 | Kristalose |
| Sobi, INC | $65.49 | 2019-2022 | |
| Seqirus USA INC | $39.65 | 2021-2023 | Flucelvax Quadrivalent |
| Kowa Pharmaceuticals America, INC. | $36.87 | 2024-2025 | Zoryve |
| Cipher Pharmaceuticals US LLC | $31.85 | 2025 | Natroba, Spinosad |
| Verrica Pharmaceuticals INC. | $26.69 | 2024 | Ycanth |
| Alexion Pharmaceuticals, INC. | $23.04 | 2025 | Koselugo |
| Phadia US INC. | $18.14 | 2019 | |
| Genentech USA, INC. | $17.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Perello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.